ClinConnect ClinConnect Logo
Search / Trial NCT06871384

Dietary Strategy to Tackle Cognitive and Locomotor Abilities in Early Elderly Subjects

Launched by UNIVERSITY ROVIRA I VIRGILI · Mar 6, 2025

Trial Information

Current as of April 29, 2025

Not yet recruiting

Keywords

Cognitive Impairment Locomotor Impairment Sarcopenia Aging Mediterrnean Diet Non Alcoholic Wine Polyphenols

ClinConnect Summary

This clinical trial, called the WinAging project, is exploring how a specific type of polyphenol found in red wine, called resveratrol, can help improve thinking and movement abilities in older adults. The researchers believe that by consuming a nonalcoholic version of red wine that contains these beneficial compounds, along with a healthy Mediterranean diet, participants may experience better cognitive function and muscle strength. They are particularly interested in how these polyphenols might positively affect the gut microbiota, which are the tiny bacteria living in our intestines, as they play a role in our overall health.

To be eligible for this study, participants must be men or women aged 60 to 74 who can tolerate the taste of red wine and are willing to give their written consent. However, those who are older than 75, have certain health conditions like diabetes or severe cognitive impairment, or have dietary allergies to Mediterranean foods cannot participate. Throughout the study, participants can expect to take a daily dose of the nonalcoholic red wine and be monitored for changes in their thinking, movement abilities, and overall health. This trial aims to uncover how diet can influence aging and help seniors maintain their independence.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Men or women between 60-74 years old; Sensory tolerance to red wine; Written informed consent provided before the initial screening visit.
  • Exclusion Criteria:
  • 1. Men or women \>75 years old,
  • 2. Hypoglucaemiant treatment or type 1 and type 2 diabetes mellitus diagnosed
  • 3. Anaemia (hemoglobin ≤13 g/dL in men and ≤12 g/dL in women)
  • 4. Subjects diagnosed of intestinal disorders such as chron disease, colitis ulcerous, and irritable bowel syndrome
  • 5. To present a clinical active chronic disease
  • 6. To present severe sarcopenia
  • 7. To present cognitive impairment (MMSE ≤ 24 or clinical diagnosis of mild cognitive impairment or dementia)
  • 8. Dietary allergies to: Mediterranean foods (eg, nuts), sulphytes or nitrates
  • 9. Use of antioxidants supplements
  • 10. Regular consumers of red wine who do not agree to change the consumption of red wine with alcohol to nonalcholized wine during the intervention
  • 11. Chronic alcoholism
  • 12. Current or past participation in a clinical trial or consumption of a research product in the 30 days prior to inclusion in the study
  • 13. Failure to follow the study guidelines. For participation in the muscle biopsy, additional exclusion criteria included: Use of prescription anti-platelet medication; Prescription anticoagulant use (or antiaggregant, or acenocoumarol; Conditions which would reduce healing; or known allergy to lidocaine.

About University Rovira I Virgili

The University Rovira i Virgili (URV) is a prestigious academic institution located in Tarragona, Spain, renowned for its commitment to research and innovation in various fields, including health sciences. With a strong emphasis on interdisciplinary collaboration, URV actively engages in clinical trials aimed at advancing medical knowledge and improving patient care. The university's research initiatives are supported by state-of-the-art facilities and a network of experienced professionals dedicated to conducting high-quality studies that adhere to ethical standards and regulatory guidelines. Through its clinical research endeavors, URV seeks to contribute to the development of new treatments and therapies, ultimately enhancing the health outcomes of diverse populations.

Locations

Reus, , Spain

Patients applied

0 patients applied

Trial Officials

Rosa Solà Alberich, Professor

Principal Investigator

Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, NFOC-Salut group, 43201 Reus, Spain Institut Investigació Sanitària Pere i Virgili (ISPV), 43204, Reus, Spain Hospital Universitari Sant Joan de Reus, 43204, Reus, Spain

Anna Pedret Figuerola, Dr.

Principal Investigator

Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, NFOC-Salut group, 43201 Reus, Spain

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported